Low Density Lipoprotein Undergoes Oxidative Modification in Vivo

Overview

Journal Proc Natl Acad Sci U S A

Specialty Science

Date 1989 Feb 1

PMID 2465552

Citations 259

Authors

W Palinski

M E Rosenfeld

S Yla-Herttuala

G C Gurtner

S S Socher

S W Butler

S Parthasarathy

T E Carew

D Steinberg

J L Witztum

Affiliations

Soon will be listed here.

Abstract

It has been proposed that low density lipoprotein (LDL) must undergo oxidative modification before it can give rise to foam cells, the key component of the fatty streak lesion of atherosclerosis. Oxidation of LDL probably generates a broad spectrum of conjugates between fragments of oxidized fatty acids and apolipoprotein B. We now present three mutually supportive lines of evidence for oxidation of LDL in vivo: (i) Antibodies against oxidized LDL, malondialdehyde-lysine, or 4-hydroxynonenal-lysine recognize materials in the atherosclerotic lesions of LDL receptor-deficient rabbits; (ii) LDL gently extracted from lesions of these rabbits is recognized by an antiserum against malondialdehyde-conjugated LDL; (iii) autoantibodies against malondialdehyde-LDL (titers from 512 to greater than 4096) can be demonstrated in rabbit and human sera.

Citing Articles

Overview of Clinical Relevance of Antibodies Against Oxidized Low-Density Lipoprotein (oLAb) Within Three Decades by ELISA Technology.

Wonisch W, Tatzber F, Lindschinger M, Falk A, Resch U, Morkl S Antioxidants (Basel). 2025; 13(12.

PMID: 39765889 PMC: 11672888. DOI: 10.3390/antiox13121560.

The Efficacy of Vitamins in the Prevention and Treatment of Cardiovascular Disease.

Tappia P, Shah A, Dhalla N Int J Mol Sci. 2024; 25(18).

PMID: 39337248 PMC: 11432297. DOI: 10.3390/ijms25189761.

Atherosclerosis antigens as targets for immunotherapy.

Raposo-Gutierrez I, Rodriguez-Ronchel A, Ramiro A Nat Cardiovasc Res. 2024; 2(12):1129-1147.

PMID: 39196152 DOI: 10.1038/s44161-023-00376-x.

Targeting leukotriene biosynthesis to prevent atherosclerotic cardiovascular disease.

Wang X, Baskaran L, Chan M, Boisvert W, Hausenloy D Cond Med. 2024; 6(2):33-41.

PMID: 38800614 PMC: 11126214.

Human In Vitro Oxidized Low-Density Lipoprotein (oxLDL) Increases Urinary Albumin Excretion in Rats.

Dabkowski K, Kreft E, Salaga-Zaleska K, Chyla-Danil G, Mickiewicz A, Gruchala M Int J Mol Sci. 2024; 25(10).

PMID: 38791535 PMC: 11122078. DOI: 10.3390/ijms25105498.

References

Young S, Bertics S, Curtiss L, Witztum J . Characterization of an abnormal species of apolipoprotein B, apolipoprotein B-37, associated with familial hypobetalipoproteinemia. J Clin Invest. 1987; 79(6):1831-41. PMC: 424527. DOI: 10.1172/JCI113025. View

Steinbrecher U . Oxidation of human low density lipoprotein results in derivatization of lysine residues of apolipoprotein B by lipid peroxide decomposition products. J Biol Chem. 1987; 262(8):3603-8. View

Wiklund O, Witztum J, Carew T, Pittman R, Elam R, Steinberg D . Turnover and tissue sites of degradation of glucosylated low density lipoprotein in normal and immunized rabbits. J Lipid Res. 1987; 28(9):1098-109. View

Carew T, Schwenke D, Steinberg D . Antiatherogenic effect of probucol unrelated to its hypocholesterolemic effect: evidence that antioxidants in vivo can selectively inhibit low density lipoprotein degradation in macrophage-rich fatty streaks and slow the progression of.... Proc Natl Acad Sci U S A. 1987; 84(21):7725-9. PMC: 299373. DOI: 10.1073/pnas.84.21.7725. View

Haberland M, Fong D, Cheng L . Malondialdehyde-altered protein occurs in atheroma of Watanabe heritable hyperlipidemic rabbits. Science. 1988; 241(4862):215-8. DOI: 10.1126/science.2455346. View

Yla-Herttuala S, Jaakkola O, Ehnholm C, Tikkanen M, Solakivi T, Sarkioja T . Characterization of two lipoproteins containing apolipoproteins B and E from lesion-free human aortic intima. J Lipid Res. 1988; 29(5):563-72. View

Goldstein J, Ho Y, Basu S, Brown M . Binding site on macrophages that mediates uptake and degradation of acetylated low density lipoprotein, producing massive cholesterol deposition. Proc Natl Acad Sci U S A. 1979; 76(1):333-7. PMC: 382933. DOI: 10.1073/pnas.76.1.333. View

Hollander W, Colombo M, Kirkpatrick B, Paddock J . Soluble proteins in the human atherosclerotic plaque. With spectral reference to immunoglobulins, C3-complement component, alpha 1-antitrypsin and alpha 2-macroglobulin. Atherosclerosis. 1979; 34(4):391-405. DOI: 10.1016/0021-9150(79)90064-9. View

Fogelman A, Shechter I, Seager J, Hokom M, Child J, Edwards P . Malondialdehyde alteration of low density lipoproteins leads to cholesteryl ester accumulation in human monocyte-macrophages. Proc Natl Acad Sci U S A. 1980; 77(4):2214-8. PMC: 348683. DOI: 10.1073/pnas.77.4.2214. View

10.

Parums D, Mitchinson M . Demonstration of immunoglobulin in the neighbourhood of advanced atherosclerotic plaques. Atherosclerosis. 1981; 38(1-2):211-6. DOI: 10.1016/0021-9150(81)90118-0. View

11.

Haberland M, Fogelman A, Edwards P . Specificity of receptor-mediated recognition of malondialdehyde-modified low density lipoproteins. Proc Natl Acad Sci U S A. 1982; 79(6):1712-6. PMC: 346050. DOI: 10.1073/pnas.79.6.1712. View

12.

Witztum J, Steinbrecher U, Fisher M, Kesaniemi A . Nonenzymatic glucosylation of homologous low density lipoprotein and albumin renders them immunogenic in the guinea pig. Proc Natl Acad Sci U S A. 1983; 80(9):2757-61. PMC: 393907. DOI: 10.1073/pnas.80.9.2757. View

13.

Curtiss L, Witztum J . A novel method for generating region-specific monoclonal antibodies to modified proteins. Application to the identification of human glucosylated low density lipoproteins. J Clin Invest. 1983; 72(4):1427-38. PMC: 370427. DOI: 10.1172/JCI111099. View

14.

Witztum J, Steinbrecher U, Kesaniemi Y, Fisher M . Autoantibodies to glucosylated proteins in the plasma of patients with diabetes mellitus. Proc Natl Acad Sci U S A. 1984; 81(10):3204-8. PMC: 345250. DOI: 10.1073/pnas.81.10.3204. View

15.

Steinbrecher U, Parthasarathy S, Leake D, Witztum J, Steinberg D . Modification of low density lipoprotein by endothelial cells involves lipid peroxidation and degradation of low density lipoprotein phospholipids. Proc Natl Acad Sci U S A. 1984; 81(12):3883-7. PMC: 345326. DOI: 10.1073/pnas.81.12.3883. View

16.

Steinbrecher U, Fisher M, Witztum J, Curtiss L . Immunogenicity of homologous low density lipoprotein after methylation, ethylation, acetylation, or carbamylation: generation of antibodies specific for derivatized lysine. J Lipid Res. 1984; 25(10):1109-16. View

17.

Jurgens G, LANG J, Esterbauer H . Modification of human low-density lipoprotein by the lipid peroxidation product 4-hydroxynonenal. Biochim Biophys Acta. 1986; 875(1):103-14. DOI: 10.1016/0005-2760(86)90016-0. View

18.

Young S, Bertics S, Scott T, Dubois B, Curtiss L, Witztum J . Parallel expression of the MB19 genetic polymorphism in apoprotein B-100 and apoprotein B-48. Evidence that both apoproteins are products of the same gene. J Biol Chem. 1986; 261(7):2995-8. View

19.

Young S, Witztum J, Casal D, Curtiss L, Bernstein S . Conservation of the low density lipoprotein receptor-binding domain of apoprotein B. Demonstration by a new monoclonal antibody, MB47. Arteriosclerosis. 1986; 6(2):178-88. DOI: 10.1161/01.atv.6.2.178. View

20.

Tsukada T, Rosenfeld M, Ross R, Gown A . Immunocytochemical analysis of cellular components in atherosclerotic lesions. Use of monoclonal antibodies with the Watanabe and fat-fed rabbit. Arteriosclerosis. 1986; 6(6):601-13. DOI: 10.1161/01.atv.6.6.601. View